Haldol Decanoat

Quick links

Choose a section

Quick links to important sections

Advertisements

Haldol Decanoat

Advertisements
Advertisements

Overview of Haldol Decanoat

Haldol Decanoat is a prescription-only, synthetic psychotropic medication classified as a long-acting typical antipsychotic designed to provide sustained therapeutic effects over an extended period. It is primarily used to stabilize key neurotransmitter activity in the brain.

Property Description
Active ingredient Haloperidol Decanoate (INN)
Form Sterile oil solution (Long-Acting Injectable, LAI)
Pharmacological class Typical Antipsychotic (First-Generation Antipsychotic, FGA)
Common use Sustained neurochemical stabilization
Origin Synthetic (Butyrophenone derivative)

What Type of Medicine is Haldol Decanoat?

Haldol Decanoat is an antipsychotic agent belonging to the butyrophenone derivatives group, formally classified as a first-generation antipsychotic (FGA). Its active substance is Haloperidol Decanoate, which is a chemically modified ester of the base drug, haloperidol. The drug is clinically recognized for its strong antagonism of central dopamine D2 receptors. This action helps regulate overactive signaling pathways involved in thought and perception.


Why is Haldol Decanoat a Long-Acting Depot Injection?

This medication is uniquely formulated as a specialized long-acting injectable (LAI), meaning it is administered as a deep intramuscular injection. The formulation is a sterile, oil-based solution, typically using sesame oil as the vehicle. This unique composition, along with the decanoate ester structure, allows the drug to be stored in the muscle tissue and slowly released into the circulation over several weeks, sustaining therapeutic levels for continuous support. This specific formulation provides a consistent, prolonged release of the active drug, differentiating it from daily oral medications.


What is the General Purpose of this Stabilizing Agent?

The general purpose of Haldol Decanoat is to help patients achieve and maintain long-term stability and continuous mental clarity. By ensuring a consistent supply of the medication via the depot, the drug provides steady neurochemical stabilization. This mechanism is typically relied upon to help suppress persistent, recurring disturbances in thought and perception, offering a reliable alternative for patients who may face difficulties with daily oral compliance.

Regulatory References

  1. MedlinePlus
Advertisements

What side effects are possible with Haldol Decanoat?

Adverse Reaction Scope

Adverse effects documented in regulatory sources, such as the FDA and EMA, are classified by frequency and body system. The most frequently reported adverse reaction is Extrapyramidal disorder, which is classified as Very Common (occurring in 1 or more in 10 patients) and includes symptoms such as parkinsonism, dystonia, and akathisia. Other Common reactions reported in regulatory documents include Injection site reactions, insomnia, agitation, and constipation.

Category High-Level Regulatory Classification
Frequency Classification Very Common: Extrapyramidal disorder. Common: Parkinsonism, Insomnia, Agitation, Constipation. Not Known: Neuroleptic Malignant Syndrome, Tardive Dyskinesia, QTc prolongation, Sudden death.
System-Organ Classes Nervous System Disorders (e.g., movement disorders, NMS), Cardiac Disorders (e.g., QTc prolongation, Torsade de pointes), and Gastrointestinal Disorders (e.g., dry mouth).

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights several serious, though rare, adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), a potentially fatal syndrome characterized by fever and muscle rigidity. Also documented are Tardive Dyskinesia, a potentially irreversible involuntary movement disorder, and severe cardiac events such as QTc Interval Prolongation and Torsade de Pointes.

Population-specific safety considerations are mandated: The drug carries an FDA Boxed Warning regarding an increased risk of death in elderly patients with dementia-related psychosis, a use for which the medicine is not approved. It is contraindicated in patients with Parkinson's disease. Furthermore, the risk of developing Tardive Dyskinesia is officially stated to increase with the duration of treatment and the total cumulative dose.

Regulatory Safety Summary

The official safety structure is defined by the high incidence of movement-related side effects and the explicit documentation of low-frequency, high-severity risks, particularly those affecting cardiac and neurological function. This framework dictates the mandated safety constraints and cautions, such as those related to cardiovascular disorders and a history of seizures.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Haldol Decanoat focuses on the exaggeration of the known pharmacological effects of its active substance, haloperidol, particularly at higher than recommended doses.

Documented Overdose Presentations

Overdose is characterized by prominent effects across key physiological systems:

  • Central Nervous System (CNS): Symptoms include severe sedation that can progress to coma, respiratory depression, and pronounced confusion. Severe extrapyramidal reactions are a key feature, manifesting as muscular rigidity or generalized tremor.
  • Cardiovascular System: Overdose carries a significant risk of hypotension and potentially life-threatening cardiac rhythm abnormalities, specifically QTc interval prolongation and Torsades de Pointes.

Required Emergency Actions

Emergency medical care is required immediately for any suspected overdose due to the risk of severe, potentially fatal, complications. Regulatory authorities mandate that continuous ECG and vital signs monitoring must be performed in a hospital setting to detect and manage these cardiovascular risks.

No specific antidote is known for haloperidol overdose. Management is symptomatic and supportive, focusing on maintaining vital functions. Treatment of severe hypotension with vasopressors must avoid epinephrine, as haloperidol may block its activity, potentially leading to paradoxical further lowering of blood pressure.

Advertisements

Therapeutic Uses of Haldol Decanoat

What Haldol Decanoat Treats: Main Uses and Benefits

Haldol Decanoat is commonly used for managing schizophrenia and related chronic psychotic conditions. It is relevant for easing symptom clusters that may become intense, such as hallucinations, delusions, and severe behavioral disorganization, which are symptoms that interfere with daily functioning. This use supports the patient during difficult episodes by easing distress and contributes to maintaining a sense of stability when symptoms are more noticeable.


Applied in clinical settings that involve chronic and persistent symptom patterns, the long-acting injectable format provides supportive relief that may contribute to a continuous therapeutic effect. This is commonly used to help with actively lowering the risk of psychotic relapse or symptomatic exacerbation, and consistent medication delivery may assist with maintaining functional stability over the long term. This medication is considered relevant when long-term compliance with a daily oral medication regimen is challenging. It contributes to easing the overall symptom load by contributing to an uninterrupted supply of medication, and may provide supportive relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Positive Psychotic Symptoms

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Haldol Decanoat?

The use of Haldol Decanoat is strictly governed by official regulatory labeling, defining the eligible patient population and those for whom the medication is restricted or contraindicated. The medication is primarily intended for adult patients (18 and above) who have previously been stabilized on an oral haloperidol product.


Absolute Contraindications

The medicine must not be used in patients with specific pre-existing conditions. These absolute exclusions include: severe toxic central nervous system (CNS) depression or comatose states; Parkinson's disease or Dementia with Lewy bodies; and certain cardiac rhythm abnormalities, such as known QTc interval prolongation or uncorrected hypokalaemia. The drug is also not approved for treating elderly patients with dementia-related psychosis (FDA Boxed Warning).

Age and Condition Restrictions

Use is restricted based on age, as the safety and efficacy have not been established for children and adolescents below 18 years of age. Furthermore, use is conditional on organ function: patients with hepatic impairment or severe renal impairment may require a lower initial dose. Individuals with severe cardiovascular disorders require particular caution.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Haloperidol Decanoate (Haldol Decanoat) is defined by pharmacokinetic alterations and significant pharmacodynamic constraints as established in official regulatory documents. Information below is based exclusively on government regulatory data.

Contraindicated and High-Risk Combinations

Co-administration with medicinal products that prolong the QTc interval is strictly contraindicated due to the documented increase in risk for serious cardiac events, including Torsades de Pointes. The combination with Lithium is associated with an official warning regarding the potential for an encephalopathic syndrome characterized by neurological toxicity.

Pharmacokinetic and Pharmacodynamic Effects

Interaction Type Interacting Substance Class Official Interaction Outcome
Pharmacokinetic CYP3A4 and/or CYP2D6 Inhibitors Increase in haloperidol plasma concentration and reduced clearance.
Pharmacokinetic CYP3A4 Inducers Decrease in haloperidol plasma concentration and increased clearance.
Pharmacodynamic Central Nervous System (CNS) Depressants Potential for additive CNS depressant effects and enhanced hypotension.
Pharmacodynamic Levodopa / Dopamine Agonists Impairment or antagonism of their therapeutic effects.

Alcohol must be avoided due to the documented risk of additive CNS depression. Furthermore, regulatory labels note that Thyrotoxicosis in patients can increase the risk of severe neurotoxicity when receiving this medication, and Haloperidol may officially lower the convulsive threshold in patients receiving anticonvulsants.

Advertisements

Mechanism of Action

How Haldol Decanoate Works


High-Affinity D2 Receptor Antagonism

The core action of haloperidol is the high-affinity blockade (antagonism) of the Dopamine D2 Receptor ( D2R) in the central nervous system. This direct antagonism suppresses the ability of dopamine to bind and activate its receptor, initiating a molecular cascade that lowers intracellular cAMP signaling. This mechanism is applied to modulate overactive dopaminergic signaling, which leads to a state of altered signal transduction within targeted neural pathways.


Non-Selective Pathway Modulation and Motor Effects

The D2 receptor antagonism is non-selective, acting equally in the mesolimbic pathway and the nigrostriatal motor pathway. While the action in the mesolimbic system results in reduced dopaminergic activity in that system, its simultaneous effect on the motor pathway creates a state of functional hypodopaminergia. This is a direct consequence of the drug’s action across all D2-expressing pathways.


Prodrug Mechanism for Sustained Release

The decanoate ester is an inactive prodrug that, following injection, undergoes slow hydrolysis to continuously release active haloperidol. This mechanism ensures the maintenance of altered signal transduction by guaranteeing sustained receptor occupancy. This prolonged effect is a crucial element of the mechanism, allowing the nervous system the time required to complete necessary adaptive changes.

Advertisements

Dosage and Administration Information

Haldol Decanoat is a sterile oil solution formulated exclusively for administration via deep intramuscular injection (IM) by a healthcare professional, and must not be administered intravenously. The drug is used as a long-acting maintenance therapy administered at a fixed interval of once every four weeks (monthly).

The dosage is not fixed but is determined by conversion from the patient’s prior stable daily oral dose, typically using a calculation factor of 10 to 20 times the oral dose. The usual maintenance range is 50 mg to 200 mg per injection. Dosage adjustments are made in increments of 50 mg or less, strictly at the 4-week interval.

A key procedural constraint involves the first injection: a maximum of 100 mg can be administered in the initial dose, and any calculated excess amount must be delayed and administered 3 to 7 days later. Furthermore, the volume injected into any single site must not exceed 3 mL. During the transition phase, oral haloperidol may need to be continued for several weeks to ensure uninterrupted medication availability.

For specific populations, such as older adults and those with hepatic impairment, it is generally advised to start at the lower end of the dosing range and perform dose adjustments with caution.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Haldol Decanoat

The overview of research evidence focuses strictly on the structure of clinical trials and scientific reviews that have evaluated Haloperidol Decanoat, using neutral language to describe what researchers observed without offering clinical advice. The evidence is drawn from controlled trials and observational studies of adult patients.


Evidence for Use in Maintenance Treatment of Schizophrenia

The clinical evaluation of Haloperidol Decanoat has primarily focused on research involving this administration method for patients with schizophrenia. Researchers have conducted Randomized Controlled Trials (RCTs) to explore research scenarios involving long-term observation of patient symptom patterns over a defined period.

What Researchers Studied: The key studies involved adult patients diagnosed with chronic, multi-episode schizophrenia or schizoaffective disorder. The primary outcomes that researchers monitored in these trials evaluated outcomes such as the rates of psychotic relapse, the incidence of hospitalization, and overall symptom change measured using standardized clinical rating scales. These controlled studies often compared the long-acting injectable against a placebo injection or against the immediate-release (oral) form of the base drug, haloperidol. Follow-up durations in these primary RCTs typically lasted up to one year (52 weeks).

What the Studies Reported (Neutral Summary): Studies conducted during periods of increased symptom activity reported that the measured outcomes showed patterns of difference in the rates of relapse between the group receiving the long-acting injection and the group receiving a placebo injection. In trials comparing the long-acting injection to the oral form of haloperidol, findings described patterns related to similar measured outcomes, with no discernible difference reported for changes in overall mental state or global impression. Research highlights changes measured during the study period, noting that a consistent supply of the medication was studied for its potential relationship to the frequency of observed symptoms or episodes.

What Remains Uncertain: Regulatory reviews note that data from some pivotal, early placebo-controlled trials were sparse and often relied on modest sample sizes. High-quality, long-term outcomes are not well characterized when compared to the evidence base available from short-term controlled trials, and the evidence base often relies on studies where follow-up durations were limited to a medium-term interval.


The Role of Long-Term Studies and Follow-up

Research has explored the duration of observation in key trials. Long-term studies are often non-randomized, meaning their results apply only to the populations studied and may not fully account for all confounding factors over many years. There is limited information for outcomes such as long-term functional recovery or patient-reported quality of life, as these endpoints have not been widely recorded in controlled trials.


Comparative Research and Placebo-Controlled Trials

Clinical studies have explored how the long-acting injection performs when compared both against no active treatment and against other established maintenance therapies.

What the Studies Reported (Neutral Summary): Comparisons between the long-acting injection and the oral form of the base drug show patterns where there were no discernible differences in measured outcomes for global impression or mental state. Comparisons with other first-generation long-acting antipsychotics also suggest that studies reported similar patterns for outcomes such as changes in overall symptoms or global impression.

What Remains Uncertain: Comparative evidence is lacking for the full range of currently available, newer long-acting injectable medications. While trials compared it to older depot formulations, the long-term data regarding its performance against many modern long-acting options remain insufficient for robust comparison across all outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Haldol Decanoat (FAQ)


Q: Is Haldol Decanoat the same as regular haloperidol?

According to official product information, Haldol Decanoat is a chemically modified version of the base drug, haloperidol. The active part of the medication is the same, meaning it shares the core mechanism of action of the base drug. The modification is what allows it to be slowly released into the body as a long-acting injection.

Q: Does Haldol Decanoat affect heart rhythm?

Regulatory documents note that this medication has been associated with potential effects on heart rhythm, specifically something called QTc interval prolongation. Serious cardiac events, such as Torsade de Pointes, have been reported in official documents. Official labeling mandates explicit safety constraints, particularly regarding patients with pre-existing cardiac conditions.

Q: How is the dose of Haldol Decanoat determined by the healthcare provider?

The dose of the Haldol Decanoat injection is determined based on the patient's stable daily dose of oral haloperidol. Healthcare providers use a conversion factor, typically around 20 times the oral dose, to establish the appropriate long-acting injection amount.

Q: What is the typical timeframe for the effects of an injection to start?

Official product information describes the onset of action as occurring within a few days after the injection is administered. Sustained therapeutic levels are maintained as the drug is slowly and consistently released from the muscle tissue over several weeks.

Q: Does Haldol Decanoat work immediately after the shot?

No. This long-acting depot injection is designed to be slowly released from the muscle over time. Therefore, the onset of action is typically observed over a period of a few days.

Q: Can Haldol Decanoat be used for things other than schizophrenia?

Official labeling indicates that in addition to mental health problems such as schizophrenia, the medication is also indicated for managing states of confusion, specifically delirium. The decision for its use is based strictly on officially approved indications.

Q: Does Haldol Decanoat cause weight gain?

Yes, regulatory documents list weight gain as a common side effect associated with treatment using haloperidol, the active ingredient in this medication.

Q: Can this medication cause sleepiness or fatigue?

Yes, official regulatory labels describe drowsiness, or sleepiness, as a common side effect of this medication. Less commonly, reports include feelings of unusual tiredness or weakness, which is known as fatigue.

Q: Will Haldol Decanoat affect my driving or operating machinery?

Official product information states that this medication can affect a person's ability to drive or operate tools and machinery. This is because side effects like feeling sleepy or drowsy may affect a person’s overall alertness and coordination.

Q: Is it normal to feel a lump or pain at the injection site?

Injection site reactions, including pain and the formation of small lumps or nodules, are documented in regulatory reports as common adverse reactions at the site where the medicine was administered.

Q: Can a person stop taking Haldol Decanoat suddenly?

Regulatory sources indicate that gradual termination of treatment is often indicated when haloperidol is discontinued. Discontinuation is assessed on a patient-by-patient basis by a healthcare provider.

Q: Can I take pain relievers (like ibuprofen or Tylenol) while on this medicine?

Regulatory data do not show a known major drug interaction between haloperidol and acetaminophen (Paracetamol/Tylenol). However, official drug labels recommend that concurrent use of all medications be assessed by a healthcare provider.

Q: Can people with liver or kidney problems use this drug?

Regulatory guidelines state that patients with hepatic impairment (liver problems) or severe renal impairment (kidney problems) should be treated with caution. This may include starting the medicine at the lower end of the dosing range, as the body's ability to clear the drug may be affected.

Q: Is it possible to be allergic to Haldol Decanoat?

Yes. The official product information specifies that the medicine is strictly contraindicated, meaning it must not be used, in patients who have a known hypersensitivity or allergy to the active substance or any of the ingredients in the injection.

Q: What should I do if I experience muscle stiffness or shaking after the injection?

Muscle stiffness, shaking, and abnormal movements are documented in official safety information as common manifestations of Extrapyramidal Disorder. This is classified as a very common adverse reaction associated with the medication.

Q: Can Haldol Decanoat interact with supplements or herbal remedies?

Yes, regulatory documents caution regarding the use of supplements and herbal remedies. Interactions may occur with substances that affect the way the body processes the medication, specifically the enzyme systems that clear the drug from the body.

Q: Does the medicine need to be refrigerated?

No. Official regulatory guidelines state that the injection must be stored at controlled room temperature and protected from light. Refrigeration and freezing are specified as inappropriate storage conditions for the medication before it is administered.

Q: Are there any specific foods or drinks to avoid while on this medicine?

Regulatory safety information advises that alcohol use is restricted due to the documented risk of additive depressant effects on the central nervous system (CNS).

Q: Can Haldol Decanoat be used during pregnancy?

Regulatory documents advise that the use of this medication during pregnancy requires caution. Official labeling states that the medicine is only indicated for use during pregnancy if the expected benefit is considered to outweigh the potential risk to the fetus.

Q: Do studies suggest Haldol Decanoat improves the long-term quality of life?

Research overviews indicate that there is limited information available on long-term outcomes, such as patient-reported quality of life. These specific endpoints have not been widely recorded in the primary controlled trials that evaluated the medication.

Q: Will I be able to feel the medication working, or is it a gradual change?

This long-acting injection is designed to achieve continuous, sustained neurochemical stabilization over a period of weeks. Because it provides a consistent, prolonged release of the active drug, the resulting change is typically a gradual stabilization rather than a sudden feeling of efficacy.

Q: How does Haldol Decanoat affect blood sugar levels?

Official recommendations include the routine monitoring of certain metabolic parameters, such as fasting blood sugar and lipids, during long-term use. This monitoring is advised due to potential metabolic side effects associated with antipsychotic drugs.

Q: Does this medicine affect sexual function?

Yes, official regulatory documents list changes to sexual function, such as decreased sexual ability, as a documented adverse reaction associated with the medication.

Q: Can Haldol Decanoat cause sensitivity to sunlight?

Yes, official safety documents list increased sensitivity of the skin to sunlight, which is called photosensitivity, as a less common adverse reaction.

Q: What should be discussed with a doctor before starting Haldol Decanoat?

Regulatory guidelines require discussion regarding absolute contraindications before treatment begins. Key conditions include Parkinson's disease, certain heart rhythm abnormalities like QTc prolongation, severe central nervous system depression, and a history of severe underlying cardiac conditions.

Q: Is there a need for routine lab tests while taking this medicine?

Yes. Due to potential side effects, routine monitoring is generally recommended during long-term use. This monitoring often includes lab tests for parameters like fasting blood sugar and lipids, as well as blood pressure and body mass index (BMI).

Q: Is it safe to use Haldol Decanoat while breastfeeding?

Limited information from authoritative sources, such as NIH databases, indicates that haloperidol levels found in milk are typically low. Monitoring the infant for potential effects such as drowsiness or sedation is noted in authoritative sources.

Advertisements

How should Haldol Decanoat be stored and disposed of?

How to Store and Dispose of Haldol Decanoate

Official regulatory guidelines strictly define the storage and disposal requirements for Haldol Decanoate injection to ensure its stability.

Storage Requirements

The medication must be stored at controlled room temperature, typically between 15 C and 30 C. It is mandatory to protect the injection from light, requiring it to be kept in its original carton until use.

Condition
Do not refrigerate
Do not freeze

Prior to administration, the solution must be visually inspected for discoloration or particulate matter, and must not be used if debris is present. The medication must also be stored out of the sight and reach of children.

Disposal

Any unused or expired Haldol Decanoate product, along with related waste material, must be disposed of in accordance with local regulatory requirements. Disposal should not be attempted via household trash or wastewater unless specifically advised by official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Haldol Decanoat found in:

A-Z Index: